Establishment Labs (ESTA) to Release Earnings on Wednesday

Establishment Labs (NASDAQ:ESTA) is projected to post its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Establishment Labs to post earnings of ($0.54) per share and revenue of $52.28 million for the quarter. Establishment Labs has set its FY 2025 guidance at EPS.Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:30 AM ET.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). The firm had revenue of $51.30 million for the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.Establishment Labs’s quarterly revenue was up 16.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.62) earnings per share. On average, analysts expect Establishment Labs to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Establishment Labs Price Performance

Shares of ESTA opened at $47.95 on Monday. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -15.72 and a beta of 0.98. Establishment Labs has a 1-year low of $26.56 and a 1-year high of $54.06. The company’s fifty day simple moving average is $42.52 and its 200 day simple moving average is $39.60. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 9.71.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Osaic Holdings Inc. raised its stake in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after acquiring an additional 1,800 shares in the last quarter. WINTON GROUP Ltd acquired a new position in shares of Establishment Labs in the second quarter valued at approximately $651,000. Nebula Research & Development LLC increased its stake in shares of Establishment Labs by 27.9% in the second quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock valued at $692,000 after buying an additional 3,538 shares during the period. Geode Capital Management LLC increased its stake in shares of Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after buying an additional 299 shares during the period. Finally, Sei Investments Co. increased its stake in shares of Establishment Labs by 13.3% in the second quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock valued at $2,068,000 after buying an additional 5,668 shares during the period. Institutional investors and hedge funds own 72.91% of the company’s stock.

Wall Street Analyst Weigh In

ESTA has been the subject of a number of research analyst reports. Canaccord Genuity Group initiated coverage on shares of Establishment Labs in a research report on Wednesday, August 20th. They set a “buy” rating and a $60.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Establishment Labs in a research report on Wednesday, October 8th. Mizuho boosted their target price on shares of Establishment Labs from $58.00 to $70.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. Citigroup reissued a “neutral” rating on shares of Establishment Labs in a research report on Tuesday, October 7th. Finally, Wall Street Zen raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a research report on Sunday, October 19th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Establishment Labs currently has an average rating of “Moderate Buy” and a consensus target price of $56.50.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.